Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zheyi Li

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Sensors (Basel, Switzerland)|February 26, 2022
A High Precision and Multifunctional Electro-Optical Conversion Efficiency Measurement System for Metamaterial-Based Thermal EmittersHeng Liu, Meng Zhao, Yongkang Gong, et al.
Vaccines|January 27, 2021
Adjuvant Selection for Influenza and RSV Prefusion Subunit VaccinesAriel Isaacs, Zheyi Li, Stacey T M Cheung, et al.
Antioxidants & Redox Signaling|October 1, 2015
PGC-1α/ERRα-Sirt3 Pathway Regulates DAergic Neuronal Death by Directly Deacetylating SOD2 and ATP Synthase βXuefei Zhang, Xiaoqing Ren, Qi Zhang, et al.
Cancer Letters|December 26, 2024
Histone lactylation-driven YTHDC1 promotes hepatocellular carcinoma progression via lipid metabolism remodelingWenfei Du, Sheng Tan, Yonglin Peng, et al.
Ebiomedicine|October 21, 2023
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
The Journal of Infectious Diseases|November 24, 2025
Safety and immunogenicity of a SARS-CoV-2 spike, subunit vaccine stabilised in the prefusion conformation by second generation Molecular Clamp evaluated in adults aged 18-55 years: a randomised, double-blind, active comparator, Phase I trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Zheyi Li, et al.
Clinical & Translational Immunology|April 12, 2021
Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2Daniel Watterson, Danushka K Wijesundara, Naphak Modhiran, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Sensors (Basel, Switzerland)|February 26, 2022
A High Precision and Multifunctional Electro-Optical Conversion Efficiency Measurement System for Metamaterial-Based Thermal EmittersHeng Liu, Meng Zhao, Yongkang Gong, et al.
Vaccines|January 27, 2021
Adjuvant Selection for Influenza and RSV Prefusion Subunit VaccinesAriel Isaacs, Zheyi Li, Stacey T M Cheung, et al.
Antioxidants & Redox Signaling|October 1, 2015
PGC-1α/ERRα-Sirt3 Pathway Regulates DAergic Neuronal Death by Directly Deacetylating SOD2 and ATP Synthase βXuefei Zhang, Xiaoqing Ren, Qi Zhang, et al.
Cancer Letters|December 26, 2024
Histone lactylation-driven YTHDC1 promotes hepatocellular carcinoma progression via lipid metabolism remodelingWenfei Du, Sheng Tan, Yonglin Peng, et al.
Ebiomedicine|October 21, 2023
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
The Journal of Infectious Diseases|November 24, 2025
Safety and immunogenicity of a SARS-CoV-2 spike, subunit vaccine stabilised in the prefusion conformation by second generation Molecular Clamp evaluated in adults aged 18-55 years: a randomised, double-blind, active comparator, Phase I trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Zheyi Li, et al.
Clinical & Translational Immunology|April 12, 2021
Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2Daniel Watterson, Danushka K Wijesundara, Naphak Modhiran, et al.
Pageof 3